Claims:

1. A therapeutic agent for impaired gastric accommodation, which comprises, as an active ingredient, a compound represented by the general formula (1):

5

10

$$\begin{array}{c|c} CH_3O & & & \\ \hline \\ CH_3O & & \\ \hline \\ CH_3O & & \\ \end{array} \begin{array}{c} NH & & \\ \hline \\ R^1 & & \\ \hline \end{array} \begin{array}{c} NH(CH_2)_nN \\ R^3 & \\ \hline \end{array} \begin{array}{c} R^2 \\ R^3 & \\ \hline \end{array} \begin{array}{c} (1) \\ \end{array}$$

(wherein R¹ represents a hydrogen atom, a hydroxyl group or a halogen atom; A represents a furyl group, a thienyl group, a thiazolyl group or an oxazolyl group; R² and R³ each represents an alkyl group with 1 to 5 carbon atoms; and n represents an integer of 2 to 4), or an acid addition salt thereof.

- 15 2. The therapeutic agent of claim 1, wherein A is a furyl group or a thiazolyl group.
 - 3. The therapeutic agent of claim 1 or 2, wherein \mathbb{R}^2 and \mathbb{R}^3 each represents an isopropyl group and n is 2.

20

25

- 4. The therapeutic agent of any one of claims 1 to 3, wherein a compound represented by the general formula (1) is 2-[N-(4,5-dimethoxy-2-hydroxybenzoyl)amino]-4-[(2-diisopropylaminoethyl)aminocarbonyl]-1,3-thiazole or an acid addition salt thereof.
- - 5. Use of a compound represented by the general

formula (1):

15

$$\begin{array}{c|c} CH_3O & & & \\ \hline \\ CH_3O & & \\ \hline \\ CH_3O & & \\ \end{array} \begin{array}{c} NH & & \\ \hline \\ R^1 & & \\ \hline \\ O & & \\ \end{array} \begin{array}{c} R^2 \\ R^3 & & \\ \hline \\ \end{array} \hspace{1cm} (1)$$

- 5 (wherein R¹ represents a hydrogen atom, a hydroxyl group, or a halogen atom; A represents a furyl group, a thienyl group, a thiazolyl group, or an oxazolyl group; R² and R³ each represents an alkyl group with 1 to 5 carbon atoms; and n represents an integer of 2 to 4), or an acid addition salt thereof to manufacture a therapeutic agent for impaired gastric accommodation.
 - 6. The use of claim 5, wherein A is a furyl group or a thiazolyl group.

7. The use of claim 5 or 6, wherein R^2 and R^3 each represents an isopropyl groups and n is 2.

- 8. The use of any one of claims 5 to 7, wherein a compound represented by the general formula (1) is 2-[N-(4,5-dimethoxy-2-hydroxybenzoyl)amino]-4-[(2-disopropylaminoethyl)aminocarbonyl]-1,3-thiazole or an acid addition salt thereof.
- 9. A method for treating impaired gastric accommodation, characterized by administration of an effective dosage of a compound represented by the general formula (1):

(wherein R¹ represents a hydrogen atom, a hydroxyl group, or a halogen atom; A represents a furyl group, a thienyl group, a thiazolyl group, or an oxazolyl group; R² and R³ each represents an alkyl group with 1 to 5 carbon atoms; and n represents an integer of 2 to 4), or an acid addition salt thereof.

10

- 10. The method of claim 9, wherein A is a furyl group or a thiazolyl group.
- 11. The method of claim 9 or 10, wherein R^2 and R^3 each represents an isopropyl group and n is 2.
 - 12. The method of claim 9, wherein a compound represented by the general formula (1) is 2-[N-(4,5-dimethoxy-2-hydroxybenzoyl)] amino]-4-[(2-
- diisopropylaminoethyl)aminocarbonyl]-1,3-thiazole or an acid addition salt thereof.